Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

913

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 2001

Conditions
Primary Breast Cancer
Interventions
DRUG

Adriamycin (Doxorubicin), Docetaxel, Tamoxifen

Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.

DRUG

Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid

Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.

Trial Locations (1)

06102

German Breast Group, Neu-Isenburg

All Listed Sponsors
collaborator

German Adjuvant Breast Cancer Group

OTHER

lead

GBG Forschungs GmbH

OTHER

NCT00793377 - Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer | Biotech Hunter | Biotech Hunter